Immunomedics
Executive Summary
Receives U.S. patent for monoclonal antibody-based therapeutic agents that localize at a tumor or infection site before becoming active. The products involve neutron capture therapy, in which boron compounds attached to the monoclonal antibodies are irradiated with attenuated neutrons to emit cytotoxic alpha particles.